(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 40.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Fennec Pharmaceuticals's revenue in 2026 is $50,999,000.On average, 8 Wall Street analysts forecast FENC's revenue for 2026 to be $2,474,040,751, with the lowest FENC revenue forecast at $2,297,854,535, and the highest FENC revenue forecast at $2,664,955,468. On average, 8 Wall Street analysts forecast FENC's revenue for 2027 to be $3,558,808,724, with the lowest FENC revenue forecast at $2,914,019,973, and the highest FENC revenue forecast at $3,922,852,798.
In 2028, FENC is forecast to generate $4,951,763,627 in revenue, with the lowest revenue forecast at $3,758,199,276 and the highest revenue forecast at $5,721,883,582.